Journal Publication

Adjuvant EGFR-TKIs plus chemotherapy cut death risk in resected NSCLC meta-analysis

A pooled analysis of five randomized trials and 890 patients found adjuvant EGFR-TKIs added to chemotherapy improved survival and disease-free survival, at the cost of more treatment-related toxicity.

A meta-analysis of five randomized controlled trials totaling 890 patients found that adding adjuvant EGFR-TKIs to chemotherapy improved overall survival and disease-free survival in resected EGFR-mutated non-small cell lung cancer.

By AppliedXLJuly 15, 2026

Executive Summary

The analysis set out to resolve whether adding EGFR-TKIs to adjuvant chemotherapy after surgery for EGFR-mutated non-small cell lung cancer improves overall survival, a question individual trials had not settled on their own.
Pooling five randomized trials showed the combination lowered the risk of death and disease recurrence, with the benefit holding consistently across patient subgroups.
The survival gain came with more treatment-related toxicity and a higher rate of stopping or reducing treatment because of side effects, a cost that a clinician weighing this regimen has to set against the benefit.
The synthesis adds weight to survival evidence for this combination in the adjuvant setting, an endpoint that has been harder to establish than disease-free survival in prior single trials.

The open question in adjuvant therapy

Whether adding EGFR-TKIs to adjuvant chemotherapy improves overall survival after resection of EGFR-mutated non-small cell lung cancer has remained an open question, even as individual trials showed disease-free survival benefits. Overall survival results have taken longer to mature and have been less consistent across single trials. The new analysis pooled randomized data specifically to settle that question with more statistical power than any one trial could provide. Adjuvant

The design: a five-trial, 890-patient pooling

The authors systematically screened six databases for randomized controlled trials comparing adjuvant EGFR-TKIs plus chemotherapy against placebo plus chemotherapy in resected EGFR-mutated NSCLC. Five trials meeting criteria, comprising 890 patients with comparable baseline age, sex, and disease stage across arms, were pooled. Overall survival and disease-free survival were prespecified as co-primary endpoints, with disease relapse and treatment-related adverse events as secondary measures. The review protocol was registered under CRD420261381478. Adjuvant

The result: significant gains on both primary endpoints

The EGFR-TKI combination improved overall survival with a hazard ratio of 0.56 (95% CI 0.41-0.77, P=0.0003) and disease-free survival with a hazard ratio of 0.36 (95% CI 0.23-0.57, P<0.0001). Both overall survival rates measured between 30 and 60 months and disease-free survival rates measured between 6 and 60 months were higher in the combination arm, and the benefit was consistent across every predefined subgroup. Fewer tumor recurrences occurred in the combination group, with the chemotherapy-alone arm showing more relapses driven predominantly by distant metastases (RR 0.37, 95% CI 0.21-0.66, P=0.0007). Adjuvant

The cost: more toxicity, more discontinuation

Treatment-related adverse events occurred more often in the combination group (RR 1.35, 95% CI 1.05-1.73, P=0.02), and toxicity-driven treatment discontinuation or dose reduction was five times more common (RR 5.00, 95% CI 1.12-22.28, P=0.03). The authors characterized this toxicity as a manageable but real trade-off against the survival gains observed, framing the combination's net benefit as one that should be weighed against the added burden of side effects. Adjuvant

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.